815 related articles for article (PubMed ID: 28921650)
21. Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.
Xu S
Pharm Res; 2015 Nov; 32(11):3577-83. PubMed ID: 26108878
[TBL] [Abstract][Full Text] [Related]
22. Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates.
Hasan MM; Laws M; Jin P; Rahman KM
Drug Discov Today; 2022 Jan; 27(1):354-361. PubMed ID: 34597756
[TBL] [Abstract][Full Text] [Related]
23. Investigational antibody drug conjugates for solid tumors.
Sapra P; Hooper AT; O'Donnell CJ; Gerber HP
Expert Opin Investig Drugs; 2011 Aug; 20(8):1131-49. PubMed ID: 21599617
[TBL] [Abstract][Full Text] [Related]
24. Bioproduction of Antibody-Drug Conjugate Payload Precursors by Engineered Cell Factories.
Wang J; Xiao H; Qian ZG; Zhong JJ
Trends Biotechnol; 2017 May; 35(5):466-478. PubMed ID: 28363408
[TBL] [Abstract][Full Text] [Related]
25. Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.
Singh SK; Luisi DL; Pak RH
Pharm Res; 2015 Nov; 32(11):3541-71. PubMed ID: 25986175
[TBL] [Abstract][Full Text] [Related]
26. Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress.
Yao HP; Zhao H; Hudson R; Tong XM; Wang MH
Drug Discov Today; 2021 Aug; 26(8):1857-1874. PubMed ID: 34224904
[TBL] [Abstract][Full Text] [Related]
27. Antibody drug conjugates: the future of chemotherapy?
Borcoman E; Le Tourneau C
Curr Opin Oncol; 2016 Sep; 28(5):429-36. PubMed ID: 27366963
[TBL] [Abstract][Full Text] [Related]
28. Catabolism of antibody drug conjugates and characterization methods.
Shadid M; Bowlin S; Bolleddula J
Bioorg Med Chem; 2017 Jun; 25(12):2933-2945. PubMed ID: 28438386
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and ADME characterizations of antibody-drug conjugates.
Lin K; Tibbitts J; Shen BQ
Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144
[TBL] [Abstract][Full Text] [Related]
30. Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
Birrer MJ; Moore KN; Betella I; Bates RC
J Natl Cancer Inst; 2019 Jun; 111(6):538-549. PubMed ID: 30859213
[TBL] [Abstract][Full Text] [Related]
31. Antibody Drug Conjugates: Preclinical Considerations.
Bornstein GG
AAPS J; 2015 May; 17(3):525-34. PubMed ID: 25724883
[TBL] [Abstract][Full Text] [Related]
32. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement.
Jiang M; Li Q; Xu B
Drug Resist Updat; 2024 Jul; 75():101086. PubMed ID: 38677200
[TBL] [Abstract][Full Text] [Related]
33. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
34. [Progress on pharmacokinetic study of antibody-drug conjugates].
Guo JJ; Gao R; Quan TF; Zhu LY; Shi B; Zhao YY; Zhu J; Li MS; Bu HZ
Yao Xue Xue Bao; 2015 Oct; 50(10):1203-9. PubMed ID: 26837163
[TBL] [Abstract][Full Text] [Related]
35. Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment.
Edupuganti VVSR; Tyndall JDATDA; Gamble AB
Recent Pat Anticancer Drug Discov; 2021; 16(4):479-497. PubMed ID: 33966624
[TBL] [Abstract][Full Text] [Related]
36. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
37. Antibody-Drug Conjugates: A promising breakthrough in cancer therapy.
Parit S; Manchare A; Gholap AD; Mundhe P; Hatvate N; Rojekar S; Patravale V
Int J Pharm; 2024 Jun; 659():124211. PubMed ID: 38750981
[TBL] [Abstract][Full Text] [Related]
38. Antibody-drug conjugates- stability and formulation.
Duerr C; Friess W
Eur J Pharm Biopharm; 2019 Jun; 139():168-176. PubMed ID: 30940541
[TBL] [Abstract][Full Text] [Related]
39. Antibody drug conjugates - Trojan horses in the war on cancer.
Iyer U; Kadambi VJ
J Pharmacol Toxicol Methods; 2011; 64(3):207-12. PubMed ID: 21843648
[TBL] [Abstract][Full Text] [Related]
40. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.
Jackson D; Stover D
Pharm Res; 2015 Nov; 32(11):3458-69. PubMed ID: 25339341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]